Phaseline

Targets › ERBB2

ERBB2 (Receptor tyrosine-protein kinase erbB-2): drug programs, companies and trials

165 programs from 118 companies in 647 trials: 348 Phase 2, 162 Phase 1, 122 Phase 3, 15 Phase 4; Oncology, Other, Genitourinary; next expected readout Nov 2026.

Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. (UniProt, P04626)

Open in Phaseline: the race on ERBB2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Michael HoppAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 4Non-squamous NSCLCDec 2026
AstraZenecaTrastuzumab deruxtecan
Receptor protein-tyrosine kinase erbB-2 binding agent; DNA topoisomerase I inhibitor
ERBB2, TOP1Phase 4BREAST CANCER; Advanced or Metastatic Breast Cancer; Breast Neoplasms; Breast Cancer; HER2-positive; Metastatic …Dec 2026
Fudan UniversityDS8201
Anti-HER2 antibody-drug conjugate
ERBB2Phase 4HER2-negative Breast CancerJan 2027
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityInetetamab
Anti-HER2 monoclonal antibody
ERBB2Phase 4Metastatic Breast CancerDec 2027
Institut Claudius RegaudTrastuzumab-Deruxtecan (T-DXd)
anti-HER2 antibody-drug conjugate with topoisomerase I inhibitor payload (DXd)
ERBB2Phase 4Locally Advanced or Metastatic Breast CancersOct 2029
Psoriasis Treatment Center of Central New JerseyDuobrii
Dual EGFR and ErbB2 inhibitor topical cream
EGFR, ERBB2Phase 4Psoriasis–
Shanghai JMT-BioKn-026 (KN026)
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Early or Locally Advanced HER2-positive Breast Cancer; First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer; Resectable HER2-positive Breast Cancer; Stomach Cancer …Nov 2026
Jiangsu HengRui MedicineSHR-A1811 for Injection
HER2-targeted antibody-drug conjugate
ERBB2Phase 3HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane; Non-Small Cell Lung Cancer With HER2- Mutations; Ovarian Cancer; HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma …Nov 2026
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin PharmaceuticalTQB2102 for injection
HER2-targeting antibody-drug conjugate (ADC) with dual epitope targeting (ECD2 and ECD4)
ERBB2Phase 3HER2-positive Breast Cancer; Metastatic Breast Cancer; Breast Cancer; Gynecological Tumors …Nov 2026
Sichuan Kelun-Biotech BiopharmaceuticalTrastuzumab Botidotin (A166)
Receptor tyrosine-protein kinase erbB-2 binding agent; Tubulin inhibitor
ERBB2, TubulinPhase 3HER2-positive Breast Cancer; Her 2 Positive Breast CancerNov 2026
RemeGenDisitamab Vedotin
Receptor tyrosine-protein kinase erbB-2 binding agent; Tubulin disrupting agent
ERBB2, TubulinPhase 3Urothelial Carcinoma; Breast Cancer; Gastric Carcinoma; Gastric Cancer …Dec 2026
Boehringer IngelheimZongertinib
HER2 inhibitor
ERBB2Phase 3Lung Cancer, Non-squamous, Non-small Cell; Non-small Cell Lung Cancer; Solid Tumours; Healthy …Dec 2026
Sichuan Baili PharmaceuticalBL-M07D1
anti-HER2 antibody-drug conjugate
ERBB2Phase 3HER2-low Breast Cancer; Gastric Adenocarcinoma; Non-squamous Non-small Cell Lung Cancer; HER2-positive Breast Cancer …Dec 2026
Jiangsu HengRui MedicinePyrotinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor
EGFR, ERBB2Phase 3Breast Cancer; Advanced Non-small Cell Lung Cancer; HER2-positive Breast Cancer; Metastatic Breast Cancer …Dec 2026
Suzhou Suncadia BiopharmaceuticalsSHR-A1811 for Injection
HER2-targeted antibody-drug conjugate
ERBB2Phase 3Advanced Colorectal Cancer; PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer; Ovarian Cancer; Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma …Dec 2026
Fudan UniversitySHR-A1811
anti-HER2 antibody-drug conjugate
ERBB2Phase 3Breast Cancer; Advanced Salivary Gland Carcinoma; Triple-negative Breast Cancer; Pancreatic Cancer …Dec 2026
Jazz PharmaceuticalsZanidatamab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Gastric Neoplasms; Metastatic HER2-positive Breast Cancer; Biliary Tract Cancer; Breast Cancer …Dec 2026
Pfizertrastuzumab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Colorectal Neoplasms; Uterine Neoplasms; Anatomic Stage IV Breast Cancer AJCC v8; Elderly Females …Dec 2026
Pfizertucatinib
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3HER2 Positive Breast Cancer; Colorectal Neoplasms; HER2-positive Breast Cancer; Uterine Neoplasms …Dec 2026
Shanghai MiracogenMRG002
anti-HER2 antibody-drug conjugate
ERBB2Phase 3Advanced or Metastatic Urothelium CancerJan 2027
Chia Tai Tianqing Pharmaceutical GroupTQB2102 for Injection
HER2 antibody-drug conjugate
ERBB2Phase 3Breast CancerJan 2027
RochePertuzumab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Solid TumorsMar 2027
Daiichi SankyoTrastuzumab Deruxtecan
Receptor protein-tyrosine kinase erbB-2 binding agent; DNA topoisomerase I inhibitor
ERBB2, TOP1Phase 3Breast Cancer; Gastric Cancer, Adenocarcinoma; Advanced Cancer; Gastric Cancer …Mar 2027
RocheTrastuzumab Emtansine
Receptor protein-tyrosine kinase erbB-2 binding agent; Tubulin inhibitor
ERBB2, TubulinPhase 3Breast Cancer; Ovarian Cancer; Metastatic Solid Tumor; Early Breast Cancer …Mar 2027
R-PharmRPH-051
HER2-directed monoclonal antibody
ERBB2Phase 3Locally Advanced Breast CancerMay 2027
Shanghai Henlius BiotechHLX22
HER2-targeted monoclonal antibody
ERBB2Phase 3Gastroesophageal-junction Cancer; HER2-low Hormone Receptor Positive Breast Cancer; HER2 + Breast CancerJun 2027
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin PharmaceuticalTQB2930 injection
Dual-epitope HER2 antibody targeting ECD2 and ECD4 epitopes
ERBB2Phase 3HER2-positive Advanced Breast Cancer; Colorectal Cancer; Advanced Solid TumorJun 2027
DualityBioDB-1303/BNT323
HER2-targeting bispecific antibody
ERBB2Phase 3HER2-positive Breast Cancer; Metastatic Breast Cancer; HER2-positive Advanced Solid TumorAug 2027
BayerBAY 2927088 (Sevabertinib)
MATE1 and MATE2-K transporter inhibitor
ERBB2, SLC47A1, SLC47A2Phase 3Advanced Non-small Cell Lung Cancer, HER2 Mutation; Advanced Solid Tumors; Healthy ParticipantsOct 2027
OSE ImmunotherapeuticsOSE2101
peptidic cancer vaccine with nine HLA-A2-restricted epitopes targeting tumor-associated an
TP53, ERBB2, CEA, MAGEA2, MAGEA3Phase 3Patients With Non-Small Cell Lung Cancer; Solid Advanced TumorDec 2027
Innovent Biologics (Suzhou)IBI354
HER2-directed antibody-drug conjugate
ERBB2Phase 3Ovarian; Locally Advanced Unresectable or Metastatic Solid TumorsDec 2027
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 3Early-stage Breast CancerFeb 2028
BioNTech SEBNT323/DB-1303
anti-HER2 antibody-drug conjugate with topoisomerase I inhibitor payload
ERBB2Phase 3Endometrial CancerMar 2028
Innovent Biopharmaceutical Technology (Hangzhou)IBI354
Anti-HER2 antibody
ERBB2Phase 3HER2-positive Breast CancerApr 2028
Region SkaneAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 3Non-Small Cell Lung CancerSep 2028
Region SkaneDacomitinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 3Non-Small Cell Lung CancerSep 2028
SystImmuneTrastuzumab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Urothelial CancerDec 2028
Suzhou Suncadia BiopharmaceuticalsTrastuzumab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Triple Negative Breast CancerDec 2030
Greenwich LifeSciencesGLSI-100
HER2/Neu peptide vaccine with GM-CSF adjuvant
ERBB2Phase 3Breast CancerDec 2031
Prof. Wolfgang JanniTrastuzumab-Deruxtecan
HER2-targeted antibody-drug conjugate (anti-HER2 ADC with topoisomerase I inhibitor payloa
ERBB2Phase 3Breast CancerApr 2032
SWOG Cancer Research NetworkHER2-targeted Therapy
HER2 receptor antagonist or antibody
ERBB2Phase 3Anatomic Stage IV Breast Cancer AJCC v8May 2032
BiocadPertuzumab (BCD-178)
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Breast Cancer–
Shanghai Henlius BiotechPertuzumab (HLX11)
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Breast Cancer; Elderly Females; Metastatic Breast Cancer; Invasive Breast Cancer …–
BioRay PharmaceuticalTrastuzumab (HS627)
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Breast Cancer–
MedSIRTrastuzumab-Deruxtecan
HER2-directed antibody-drug conjugate with topoisomerase I inhibitor payload
ERBB2Phase 2Breast CancerNov 2026
RenJi Hospital[18F]F-RESCA-RCCB6
Trop2/HER2-targeted PET imaging agent
CD70, TROP2, TACSTD2, ERBB2Phase 2Urologic Neoplasms; Renal Cancer; Solid Tumor; Breast CancerNov 2026
National University Hospital, SingaporeAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2NSCLCDec 2026
Yale UniversityAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2HER2/Neu+ Uterine Serous CarcinomaDec 2026
AmbrxAnvatabart Opadotin (ARX788)
Tubulin inhibitor; Receptor protein-tyrosine kinase erbB-2 binding agent
Tubulin, ERBB2Phase 2HER2 Positive Metastatic Breast Cancer; Breast Neoplasms; HER2-positive, Metastatic Breast Cancer; HER2-positive Breast Cancer …Dec 2026
Ruth O'ReganNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Breast CancerDec 2026
Fudan UniversityDV
anti-HER2 antibody-drug conjugate
ERBB2Phase 2Renal InsufficiencyDec 2026
Tianjin Medical University Second Hospitaldisitamab-vedotin (RC48)
anti-HER2 antibody-drug conjugate
ERBB2Phase 2Neoadjuvant ImmunotherapyDec 2026
Abscint NV/SA68Ga-ABS011
single domain antibody (sdAb) targeting HER2 labeled with gallium-68 for PET imaging
ERBB2Phase 2Metastatic Breast CancerDec 2026
The First Affiliated Hospital with Nanjing Medical UniversityDisitamb Vedotin
HER2-targeting antibody-drug conjugate
ERBB2Phase 2Breast CancerDec 2026
Shenyang Sunshine PharmaceuticalSSGJ-705
Anti-PD-1 and anti-HER2 bispecific antibody
PDCD1, ERBB2Phase 2Locally Advanced, Recurrent or Metastatic Malignancies; Locally Advanced (Unresectable) or Metastatic Solid TumorsDec 2026
Partner TherapeuticsZenocutuzumab (MCLA-128)
ErbB-2/ErbB-3 heterodimer inhibitor
ERBB2, ERBB3Phase 2Solid Tumours Harboring NRG1 FusionDec 2026
National Cancer Institute (NCI)Afatinib Dimaleate
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Advanced LymphomaJan 2027
Aston Sci.AST-301 (pNGVL3-hICD)
Therapeutic cancer vaccine expressing human ICD (immunogenic cell death)
ERBB2Phase 2Gastric CancerFeb 2027
H. Lee Moffitt Cancer Center and Research InstituteAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Squamous Cell CarcinomaFeb 2027
H. Lee Moffitt Cancer Center and Research InstituteHER-2 pulsed DC1
HER2-directed dendritic cell vaccine
ERBB2Phase 2HER2-positive Breast CancerFeb 2027
National Cancer Institute (NCI)Neratinib Maleate
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Malignant Female Reproductive System Neoplasm; Metastatic Malignant Solid NeoplasmFeb 2027
Shanghai Zhongshan HospitalHLX22
Anti-HER2 monoclonal antibody (dual HER2 blockade with trastuzumab)
ERBB2Phase 2Metastatic PDACMar 2027
Gangnam Severance HospitalHerzuma
anti-HER2 monoclonal antibody
ERBB2Phase 2HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 StudyMar 2027
National Cancer Centre, SingaporeDacomitinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2NSCLC Stage IIIB; Advanced Solid TumoursApr 2027
Latin American Cooperative Oncology GroupPHESGO
HER2-targeting dual monoclonal antibody combination (pertuzumab and trastuzumab)
ERBB2Phase 2Breast CancerApr 2027
MedSIRPHESGO (Pertuzumab-Trastuzumab fixed dose combination)
Combination of anti-HER2 antibody (trastuzumab) and anti-HER2 dimerization inhibitor (pert
ERBB2Phase 2HER2-positive Breast CancerApr 2027
City of Hope Medical CenterLapatinib ditosylate
Receptor protein-tyrosine kinase erbB-2 inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ERBB2, EGFRPhase 2Breast NeoplasmsApr 2027
Shanghai Chest HospitalDacomitinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Non-small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer (NSCLC)May 2027
CriteriumTrastuzumab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 2Breast CancerJun 2027
Shenyang Sunshine PharmaceuticalSSGJ-612
HER2-targeting agent
ERBB2Phase 2Locally Advanced (Unresectable) or Metastatic Solid Tumors; Metastatic Breast Cancer; Advanced Malignant TumorsJun 2027
RocheTrastuzumab Emtansine
Receptor protein-tyrosine kinase erbB-2 binding agent; Tubulin inhibitor
ERBB2, TubulinPhase 2Neoplasm MetastasisJun 2027
Dana-Farber Cancer InstituteMargetuximab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 2Breast CancerJul 2027
Chengdu SciMount PharmatechSMP-656
HER2-targeted antibody-drug conjugate (ADC)
ERBB2Phase 2HER2-positive Breast CancerJul 2027
University Health Network, TorontoNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Breast CancerJul 2027
H. Lee Moffitt Cancer Center and Research InstituteDendritic Cell Vaccine (DCV)
Dendritic cell vaccine targeting HER2
ERBB2Phase 2Breast Cancer Female; Leptomeningeal DiseaseAug 2027
University of Texas Southwestern Medical CenterAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Advanced Squamous Non Small Cell Lung CancerSep 2027
University of RochesterNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Breast CancerSep 2027
Centre Henri Becquerel[68Ga]Ga-NOTA-anti-HER2-sdAb
anti-HER2 single domain antibody PET/CT imaging agent
ERBB2Phase 2Breast CancerSep 2027
Fondazione Ricerca TraslazionaleTedopi
Cancer vaccine inducing cytotoxic T-lymphocytes against tumor-associated antigens (CEA, p5
CEA, TP53, ERBB2, MAGE2, MAGE3Phase 2Metastatic Non Small Cell Lung CancerSep 2027
National Taiwan University HospitalAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2NSCLC Stage IVOct 2027
Gruppo Oncologico del Nord-OvestTrastuzumab-Deruxtecan
Anti-HER2 antibody-drug conjugate with DXd payload
ERBB2Phase 2Colorectal CancerOct 2027
Memorial Sloan Kettering Cancer Center89Zr-ss-pertuzumab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 2Breast Cancer; HER-2 Positive Malignant Carcinoma of BreastNov 2027
Massachusetts General HospitalAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Lung Cancer; Advanced Solid TumorDec 2027
H. Lee Moffitt Cancer Center and Research InstituteWOKVAC
pUMVC3-based vaccine targeting IGFBP2, HER2, and IGF1R
IGFBP2, ERBB2, IGF1RPhase 2Breast Cancer FemaleDec 2027
Shandong Public Health Clinical CenterAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Carcinoma, Non-Small-Cell LungDec 2027
Henan Cancer HospitalInetetamab
Anti-HER2 monoclonal antibody
ERBB2Phase 2Breast NeoplasmsJan 2028
Centre Leon BerardLapatinib
Receptor protein-tyrosine kinase erbB-2 inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ERBB2, EGFRPhase 2Malignant Solid NeoplasmsJan 2028
David Reardon, MDNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2GlioblastomaFeb 2028
Shenyang Sunshine PharmaceuticalHER2-targeted ADC
HER2-targeted antibody-drug conjugate
ERBB2Phase 2Metastatic Breast CancerFeb 2028
H. Lee Moffitt Cancer Center and Research InstituteNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2GastroEsophageal CancerMar 2028
Roswell Park Cancer InstituteAnti-HER2/HER3 Dendritic Cell Vaccine
Dendritic cell vaccine targeting HER2 and HER3
ERBB2, ERBB3Phase 2Anatomic Stage IV Breast Cancer AJCC v8May 2028
Jiangsu HengRui MedicineTrastuzumab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 2Unresectable Locally Recurrent Breast CancerJun 2028
Seoul National University HospitalSamfenet (Trastuzumab-biosimilar)
HER2-targeted monoclonal antibody
ERBB2Phase 2Advanced Breast CancerJun 2028
Tianjin Medical University Cancer Institute and HospitalSHR-A1811
Anti-HER2 antibody-drug conjugate
ERBB2Phase 2Advanced Breast Cancer With Ultra-Low HER2 ExpressionSep 2028
Fudan UniversitySKB264
HER2-targeting antibody
ERBB2Phase 2HER2-positive, Unresectable, Locally Advanced or Metastatic Breast CancerSep 2028
Sichuan Baili PharmaceuticalPertuzumab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 2HER2-positive Breast CancerDec 2028
Henan Cancer HospitalSHR-A1811
anti-HER2 antibody-drug conjugate (ADC)
ERBB2Phase 2Metastatic Breast Cancer; Breast Cancer Early Stage Breast Cancer (Stage 1-3); HER2 Low Breast CarcinomaDec 2028
Second Affiliated Hospital, Zhejiang University, School of MedicineTrastuzumab-rezetecan (SHR-A1811)
HER2-targeted antibody-drug conjugate (ADC)
ERBB2Phase 2HER2-positive Early Breast CancerDec 2028
Henan Cancer HospitalPatuzumab
Anti-HER2 monoclonal antibody
ERBB2Phase 2Breast CancerJun 2029
Fudan UniversityNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Breast Cancer With Brain MetastasisAug 2029
Scott R. Plotkin, MD, PhDNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Neurofibromatosis Type 2Dec 2029
Spanish Breast Cancer Research GroupNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Early-stage Breast CancerJan 2030
Vanderbilt-Ingram Cancer CenterNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Anatomic Stage I Breast CancerApr 2030
Dartmouth-Hitchcock Medical CenterNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Advanced Breast CancerOct 2030
Pieris PharmaceuticalsCinrebafusp alfa (PRS-343)
HER2/4-1BB bispecific antibody
ERBB2, TNFRSF9Phase 2HER2-positive Gastric Cancer–
Baylor Breast Care CenterLapatinib
Receptor protein-tyrosine kinase erbB-2 inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ERBB2, EGFRPhase 2Breast Cancer–
UNICANCERSapitinib (AZD8931)
Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor tyrosine-protein kinase erbB-3 inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ERBB2, ERBB3, EGFRPhase 2Metastatic Breast Cancer–
Anbogen TherapeuticsABT-101
HER2 tyrosine kinase inhibitor
ERBB2Phase 1Advanced Solid TumorNov 2026
RenJi Hospital[18F]F-RESCA-RB14
Trop2/HER2-targeted PET imaging agent
TACSTD2, ERBB2Phase 1Breast CancerNov 2026
AP BiosciencesAP402
HER2-targeting immunoconjugate
ERBB2Phase 1Advanced Solid TumorDec 2026
Jeeyun LeeAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Stomach NeoplasmDec 2026
ExpreS2ion BiotechnologiesES2B-C001
HER2-expressing cancer vaccine
ERBB2Phase 1Breast CancerDec 2026
Iksuda TherapeuticsIKS014
anti-HER2 antibody-drug conjugate (MMAF payload)
ERBB2Phase 1Breast CancerDec 2026
Sunshine Guojian Pharmaceutical (Shanghai)SSGJ-705
anti-PD-1 and anti-HER2 bispecific antibody
PDCD1, ERBB2Phase 1Locally Advanced, Recurrent or Metastatic MalignanciesDec 2026
Chia Tai Tianqing Pharmaceutical GroupTQB2930 for injection
HER2 bispecific antibody
ERBB2Phase 1Metastatic Breast CancerDec 2026
Baylor College of MedicineHER2-specific CAR VST (CAR T cells)
HER2-directed chimeric antigen receptor T cells (cytotoxic T lymphocytes)
ERBB2Phase 1Bladder Cancer; Sarcoma; Brain Tumor, RecurrentDec 2026
Shanghai Institute Of Biological ProductsSIBP-A17
HER2-targeted antibody-drug conjugate (ADC)
ERBB2Phase 1Advanced Solid TumorDec 2026
Chinese PLA General HospitalHypoSti.CAR-HER2 T cells
HER2-targeted CAR-T cells with hypoxia-stimulated CAR expression system
ERBB2Phase 1HER2 Positive Advanced Solid TumorsDec 2026
Affibody[177Lu]Lu-ABY-271
HER2-targeted Affibody fusion with lutetium-177 radioisotope
ERBB2Phase 1Metastatic Breast CancerJan 2027
Enliven TherapeuticsELVN-002
HER2 kinase inhibitor
ERBB2Phase 1HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Breast CancerJan 2027
NuvalentNVL-330
HER2 tyrosine kinase inhibitor
ERBB2Phase 1Locally Advanced Solid TumorJan 2027
City of Hope Medical CenterHER2-CAR T cells
HER2-targeted chimeric antigen receptor T-cell therapy
ERBB2Phase 1Malignant NeoplasmJan 2027
Myeloid TherapeuticsMT-304
mRNA-LNP encoding HER2-targeted immunotherapy
ERBB2Phase 1HER2-Expressing Solid TumorsJan 2027
Beijing BiotechEB-G3B7-NK dual-target CAR-NK cells
Dual-targeting CAR-NK cells directed against IL13Rα2, EGFR/EGFRvIII, or B7-H3 (CD276) expr
CD276, MSLN, EGFR, ERBB2, IL13RA2Phase 1Non-Small Cell Lung Cancer; Breast Cancer (Locally Advanced or Metastatic); Glioblastoma; Advanced Hepatocellular Carcinoma (HCC) …Feb 2027
Beijing BiotechEB-DT-CAR-NK
Dual-target CLDN18.2/HER2 CAR-NK cells
CLDN18, ERBB2Phase 1Advanced Gastric AdenocarcinomaMar 2027
Beijing BiotechEB-DUO-CAR-NK-CEA/GCC
Dual-target CAR-NK cell therapy targeting CEA and GUCY2C (or CEA and HER2, or GUCY2C and H
CEACAM5, GUCY2C, ERBB2, CEA, HER2, IL15Phase 1Colorectal Cancer; Colorectal Cancer MetastaticMar 2027
Beijing BiotechEB-HC01 dual-target CAR-NK cells
Allogeneic dual-target CAR-NK cells targeting HER2 and CEA/CEACAM5
ERBB2, CEACAM5Phase 1CholangiocarcinomaMar 2027
Beijing BiotechEBNK-1822H2
Dual-target CLDN18.2/HER2 CAR-NK cells
CLDN18A2, ERBB2Phase 1Recurrent or Metastatic Esophageal AdenocarcinomaMar 2027
Beijing BiotechEGFR/HER2 Dual-Target CAR-NK Cells
Allogeneic donor-derived NK cells engineered to express dual EGFR/HER2 chimeric antigen re
EGFR, ERBB2Phase 1Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaMar 2027
RocheRunimotamab
HER2-targeting bispecific antibody
ERBB2Phase 1Solid TumorsApr 2027
National Cancer Institute (NCI)Lapatinib
Receptor protein-tyrosine kinase erbB-2 inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ERBB2, EGFRPhase 1Metastatic Thyroid Gland CarcinomaMay 2027
Memorial Sloan Kettering Cancer CenterRat HER2 DNA
Xenogeneic HER2/neu DNA immunization
ERBB2Phase 1Breast CancerMay 2027
West China HospitalAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1HNSCC; Esophagus CancerMay 2027
Merck & Co. (MSD)Infinatamab Deruxtecan (I-DXd, MK-2400)
HER2-targeting antibody-drug conjugate
ERBB2Phase 1Oesophageal Squamous Cell Carcinoma; Small Cell Lung Cancer Extensive Stage; Esophageal Squamous Cell CarcinomaJun 2027
Beijing BiotechEB-DT-NK-UC101
Allogeneic dual-target Nectin-4/HER2 CAR-NK cells with inducible caspase-9 safety switch
NECTIN4, ERBB2Phase 1Bladder CancerJun 2027
Fox Chase Cancer CenterNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Gastric CancerJun 2027
HighField BiopharmaceuticalsHF158K1
Liposomal doxorubicin with HER2-directed trastuzumab Fab fragment
ERBB2Phase 1Solid Tumors, AdultJun 2027
CSPC Megalith BiopharmaceuticalSYS6045
HER2-targeted therapy
ERBB2Phase 1Advanced Solid TumorsJul 2027
Memorial Sloan Kettering Cancer CenterNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Solid TumorOct 2027
Virginia Commonwealth UniversityNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Advanced Solid TumorOct 2027
Essen BiotechCD146/HER2 CAR-T cells
Dual CAR-T cells targeting CD146 and HER2
MCAM, ERBB2Phase 1SarcomaDec 2027
Suzhou Biomissile PharmaceuticalsBM230
HER2-targeting biotherapeutic
ERBB2Phase 1Solid TumorDec 2027
M.D. Anderson Cancer CenterIzalontamab Brengitecan
Anti-HER2 antibody-drug conjugate
ERBB2Phase 1Non-small Cell Lung CancerDec 2027
Mayo ClinicMulti-epitope HER2 Peptide Vaccine H2NVAC
HER2-specific helper T-cell epitope vaccine
ERBB2Phase 1Breast Ductal Carcinoma In SituDec 2027
Johann Wolfgang Goethe University HospitalNK-92/5.28.z
HER2-targeted CAR-NK cell therapy
ERBB2Phase 1GlioblastomaDec 2027
YuhanYH42946
Dual EGFR exon 20 insertion and HER2 inhibitor
EGFR, ERBB2Phase 1NSCLC (Non-small Cell Lung Cancer)Mar 2028
YuhanYH32367
HER2-targeted therapy
ERBB2Phase 1HER2-Positive Solid TumorMar 2028
Cogent BiosciencesCGT4255
Selective ERBB2 inhibitor
ERBB2Phase 1Advanced Solid Tumor, AdultMay 2028
Baylor College of MedicineHER2 CAR T cells
anti-HER2 CAR T cell therapy
ERBB2Phase 1SarcomaJun 2028
HighField BiopharmaceuticalsHF50
Liposome-encapsulated bifunctional therapeutic; HER2-redirected T-cell engager with TLR7/8
ERBB2, TLR7, TLR8Phase 1Advanced Solid TumorsJun 2028
National University Hospital, SingaporeEpo-R-CD19 CAR T
CAR-T cell therapy targeting CD19 and Epo-R expressing B cell lymphoma cells
ERBB2, CD19Phase 1B-cell Lymphoma RefractoryOct 2028
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Fanconi AnemiaDec 2028
D3 Bio (Wuxi)D3L-001
Anti-HER2 antibody
ERBB2Phase 1HER-2 Positive Advanced Solid TumorsDec 2028
Fudan UniversityGQ1001
HER2-targeted antibody-drug conjugate
ERBB2Phase 1Advanced/ Metastatic Her-2 Positive Breast CancerDec 2028
Baylor College of MedicineHTR2 T Cells
TRAIL-R2 and HER2 bi-specific chimeric antigen receptor (CAR) T cells
TRAIL-R2, ERBB2Phase 1Breast CancerJan 2029
Fate TherapeuticsFT825
HER2-directed CAR-T cell therapy
ERBB2Phase 1Advanced Solid TumorMay 2029
BioNTech SEBNT323
HER2-targeted antibody-drug conjugate (trastuzumab conjugated with panmitrimer)
ERBB2Phase 1Locally Advanced Breast CancerAug 2029
Pravin T.P KaumayaMVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines
HER2 peptide vaccine
ERBB2Phase 1Breast CancerDec 2029
Pravin T.P KaumayaMVF-HER-2 (597-626) and MVF-HER-2 (266-296) vaccine emulsified with ISA 51
HER-2 peptide vaccine targeting HER-2 epitopes; administered with Montanide ISA 51 adjuvan
ERBB2Phase 1Metastatic Breast CancerDec 2029
University of VirginiaHER2 BATs
HER2-targeted bispecific activated T-cells
ERBB2Phase 1Metastatic Breast CancerJan 2031
Baylor College of MedicineAutologous CAR Positive T cells
HER2-specific chimeric antigen receptor (CAR) expressing T cells
ERBB2Phase 1SarcomaJul 2032
Children's Oncology GroupHER2 Specific CAR T Cell
anti-HER2 CAR-T cell therapy
ERBB2Phase 1EpendymomaMar 2033
Vironexis BiotherapeuticsVNX-202
Adeno-associated viral vector encoding CD3/HER2 bi-specific T-cell engager
CD3, ERBB2Phase 1HER2 Expressing Solid TumorsSep 2033
Seattle Children's HospitalHER2-specific chimeric antigen receptor (CAR) T cell
HER2-specific CAR T cell therapy with EGFRt suicide gene
ERBB2Phase 1Central Nervous System Tumor, PediatricJul 2039
China Medical University HospitalAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Non-small Cell Lung Cancer–

Conditions

Breast Cancer (116) HER2-positive Breast Cancer (42) Metastatic Breast Cancer (22) Gastric Cancer (16) Breast Neoplasms (12) HER2 + Breast Cancer (11) Advanced Solid Tumor (10) Ovarian Cancer (7) Non-small Cell Lung Cancer (7) Advanced Breast Cancer (7) HER2-positive Gastric Cancer (6) Biliary Tract Cancer (6)

Modalities

mixed (62), small molecule (59), antibody (22), other (10), protein or peptide (5)

Companies

Beijing Biotech (7) Fudan University (6) H. Lee Moffitt Cancer Center and Research Institute (5) Roche (4) Baylor College of Medicine (4) National Cancer Institute (NCI) (3) Memorial Sloan Kettering Cancer Center (3) Henan Cancer Hospital (3) Jiangsu HengRui Medicine (3) Shenyang Sunshine Pharmaceutical (3) Suzhou Suncadia Biopharmaceuticals (2) Pfizer (2) Sichuan Baili Pharmaceutical (2) Shanghai Henlius Biotech (2) Pravin T.P Kaumaya (2) Region Skane (2) Chia Tai Tianqing Pharmaceutical Group (2) Yuhan (2) RenJi Hospital (2) National University Hospital, Singapore (2)

Related targets

EGFR (42) ERBB4 (32) Tubulin (5) CEA (3) ERBB3 (3) TOP1 (2) PDCD1 (2) TACSTD2 (2) TP53 (2) CEACAM5 (2) CLDN18 (1) MCAM (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.